Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.355 USD | -1.63% | +3.15% | +41.48% |
Financials (USD)
Sales 2024 * | 334M | Sales 2025 * | 390M | Capitalization | 1.5B |
---|---|---|---|---|---|
Net income 2024 * | 67M | Net income 2025 * | 114M | EV / Sales 2024 * | 4.49 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 3.84 x |
P/E ratio 2024 * |
21.9
x | P/E ratio 2025 * |
12.9
x | Employees | 624 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.46% |
Latest transcript on ADMA Biologics, Inc.
1 day | -1.07% | ||
1 week | +6.95% | ||
Current month | -2.12% | ||
1 month | +2.70% | ||
3 months | +27.92% | ||
6 months | +101.88% | ||
Current year | +42.92% |
Managers | Title | Age | Since |
---|---|---|---|
Adam Grossman
CEO | Chief Executive Officer | 47 | 06-06-01 |
Compliance Officer | 37 | 10-12-31 | |
Skyler Bloom
IRC | Investor Relations Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Lawrence Guiheen
BRD | Director/Board Member | 73 | 12-07-23 |
Bryant Fong
BRD | Director/Board Member | 51 | 12-04-30 |
Steven Elms
CHM | Chairman | 60 | 06-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.07% | 0 M€ | 0.00% | - | |
0.04% | 0 M€ | 0.00% | - | |
0.01% | 9 M€ | +6.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 6.395 | -1.01% | 471 143 |
24-04-24 | 6.46 | -1.22% | 1,716,472 |
24-04-23 | 6.54 | +5.48% | 2,752,319 |
24-04-22 | 6.2 | -1.12% | 2,301,644 |
24-04-19 | 6.27 | +1.13% | 3,411,885 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+42.92% | 1.5B | |
-2.86% | 87.31B | |
+3.95% | 40.86B | |
-21.94% | 29.36B | |
+54.37% | 24.49B | |
-5.41% | 17.31B | |
-44.23% | 11.26B | |
-17.60% | 11.62B | |
-13.96% | 11.31B | |
+6.52% | 8.31B |
- Stock Market
- Equities
- ADMA Stock